CF PharmTech, Inc. disclosed that it bought back 17,500 H-shares on 14 May 2026 via on-market transactions, paying an aggregate HKD 0.37 million at prices ranging between HKD 20.68 and HKD 21.42 per share. The volume-weighted average cost stood at HKD 20.96 per share.

Following the transaction, the company’s issued share capital (excluding treasury shares) declined marginally by 0.0058 % to 301.47 million shares. Treasury share holdings increased from 735,500 to 753,000 shares, while total issued shares remained unchanged at 302.22 million.

The repurchase was executed under the mandate granted on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. Cumulative buybacks under this mandate now total 753,000 shares, representing 0.25 % of the shares in issue on the mandate date.

In accordance with Hong Kong Stock Exchange rules, CF PharmTech is subject to a moratorium on new share issues or sales of treasury shares until 13 June 2026.